Home › Companies › RIGEL PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 22, 2025: 4 items on RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed May 23, 2025: 2 elected · 2 approved.
Notable dissent: 1 other board item (34.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore RIGEL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RIGEL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kamil Ali-Jackson | 10,542,422 | -- | 199,277 | 227,808 | 2,860,105 | 98% | Elected | — |
| Elect Director: Jane Wasman | 10,380,140 | -- | 202,144 | 387,223 | 2,860,105 | 96% | Elected | — |
| Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. | 6,856,776 | 3,591,569 | 521,162 | -- | 2,860,105 | 66% | Approved | — |
| Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | 9,388,816 | 993,913 | 586,778 | -- | 2,860,105 | 90% | Approved | — |
Source: RIGEL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
170 asset managers disclosed a vote on at least one RIGEL PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RIGEL PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jane Wasman
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jane Wasman”): 10,380,140 for, 387,223 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2028 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 3,650,123 for, 39,111 against, 8,866 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Mixed |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 10,837 | 0 | 0 | 0 | For |
| Global X | 10,358 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 9,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Kamil Ali-Jackson
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kamil Ali-Jackson”): 10,542,422 for, 227,808 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the nominees for director, to serve until the Company's 2028 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 3,657,761 for, 31,473 against, 8,866 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Mixed |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 10,837 | 0 | 0 | 0 | For |
| Global X | 10,358 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 9,636 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
66% Approved · of votes cast
Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 700,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 6,856,776 for, 3,591,569 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 2,764,297 for, 924,937 against, 8,866 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 0 | 275,324 | 0 | 0 | Against |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 160,000 | 0 | 0 | Against |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 114,310 | 0 | 0 | Against |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Mixed |
| BRIDGEWAY FUNDS INC | 0 | 46,520 | 0 | 0 | Against |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 0 | 36,921 | 0 | 0 | Against |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 0 | 33,396 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 0 | 28,804 | 0 | 0 | Against |
| Lincoln Financial | 0 | 24,236 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 0 | 23,424 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 23,213 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 13,328 | 0 | 0 | Against |
| Legg Mason | 0 | 11,580 | 0 | 0 | Against |
| Lazard | 0 | 10,837 | 0 | 0 | Against |
| Global X | 10,358 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 152 | 9,484 | 0 | 0 | Against |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
90% Approved · of votes cast
Prior year: 74.0% for (May 24, 2024 meeting) ▲ 16.4 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 9,388,816 for, 993,913 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 61,567 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 46,520 | 0 | 0 | Against |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 0 | 10,837 | 0 | 0 | Against |
| Global X | 10,358 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 9,484 | 152 | 0 | 0 | For |
Fund voting reports, all 59 managers: 3,620,057 for, 66,903 against, 8,866 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,237,013 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,125,601 | 0 | 0 | 0 | For |
| BlackRock | 702,222 | 4,380 | 0 | 0 | For |
| State Street | 626,121 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 409,282 | 0 | 0 | 0 | For |
| Hillsdale Investment Management Inc. | 191,364 | 0 | 0 | 0 | For |
| SEI | 171,363 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 160,000 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 156,059 | 0 | 0 | 0 | For |
| Renaissance | 128,874 | 0 | 0 | 0 | For |
| Northern Trust | 127,454 | 0 | 0 | 0 | For |
| Lazard | 0 | 120,738 | 0 | 0 | Against |
| Nuveen | 115,218 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 92,503 | 0 | 0 | 0 | For |
| ZACKS INVESTMENT MANAGEMENT | 90,147 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 72,509 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 57,070 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 54,930 | 0 | 0 | 0 | For |
| Voya | 54,917 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 47,470 | 0 | 0 | Against |
| Prudential/PGIM | 46,269 | 0 | 0 | 0 | For |
| GLOBEFLEX CAPITAL L P | 45,152 | 0 | 0 | 0 | For |
| Wellington | 44,574 | 0 | 0 | 0 | For |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0 | 40,014 | 0 | 0 | Against |
Institutional-manager reports, all 131 managers: 6,233,276 for, 247,105 against, 137 abstained. Showing the 25 largest; every one is in the interactive database (link above).
93% of fund votes cast · no official result
Description as filed by funds: To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
The 60 asset managers below reported 3,426,043 for, 263,191 against, 8,866 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 0 | 171,118 | 0 | 0 | Against |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 66,337 | 0 | 0 | Against |
| Equitable | 61,567 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 0 | 10,837 | 0 | 0 | Against |
| Global X | 0 | 10,358 | 0 | 0 | Against |
| PACE SELECT ADVISORS TRUST | 9,484 | 152 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 17,710,216 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.67% |
| 2 | BlackRock | 4.86% |
| 3 | Fidelity | 2.05% |
| 4 | State Street | 1.55% |
| 5 | SEI | 0.97% |
| 6 | Delaware/Macquarie | 0.90% |
| 7 | TIAA | 0.65% |
| 8 | Pacer Funds Trust | 0.65% |
| 9 | Charles Schwab | 0.37% |
| 10 | Equitable | 0.35% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 6.98% |
| 2 | Soleus Capital Management, L.P. | 6.36% |
| 3 | BlackRock | 3.99% |
| 4 | State Street | 3.54% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.31% |
| 6 | Hillsdale Investment Management Inc. | 1.08% |
| 7 | SEI | 0.97% |
| 8 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 0.90% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.88% |
| 10 | Renaissance | 0.73% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 1,732,604 | 9.78% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 1,536,987 | 8.68% | Form 13F, quarter ended March 31, 2025 |
| Armistice Capital, LLC | 1,280,000 | 7.23% | Schedule 13G, filed May 15, 2026 |
| Vanguard Group | 1,028,072 | 5.80% | Form 13F, quarter ended March 31, 2025 |
| State Street | 637,034 | 3.60% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 411,168 | 2.32% | Form 13F, quarter ended March 31, 2025 |
| Renaissance Technologies | 201,146 | 1.14% | Form 13F, quarter ended March 31, 2025 |
| Northern Trust | 142,459 | 0.80% | Form 13F, quarter ended March 31, 2025 |
| Invesco | 134,072 | 0.76% | Form 13F, quarter ended March 31, 2025 |
| Charles Schwab | 66,337 | 0.37% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 17,710,216 shares outstanding, as reported by RIGEL PHARMACEUTICALS INC. on its Form 10-K dated December 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At RIGEL PHARMACEUTICALS INC.'s shareholder meeting held May 22, 2025, in the 2024-2025 proxy season, 170 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 909 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — RIGEL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RIGEL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RIGEL PHARMACEUTICALS INC.’s 10-K dated December 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
RIGEL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “RIGEL PHARMACEUTICALS (RIGL) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rigel-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.